Intellia Therapeutics (NASDAQ: NTLA) completed patient enrollment in its global Phase 3 HAELO study of lonvoguran ziclumeran for hereditary angioedema ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE